BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 27034082)

  • 21. Proton pump inhibitors: Understanding the associated risks and benefits of long-term use.
    Thurber KM; Otto AO; Stricker SL
    Am J Health Syst Pharm; 2023 Apr; 80(8):487-494. PubMed ID: 36629265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: a prospective open label comparative study.
    Bahtiri E; Islami H; Hoxha R; Gashi A; Thaçi K; Karakulak Ç; Thaçi S; Qorraj Bytyqi H
    Turk J Gastroenterol; 2017 Mar; 28(2):104-109. PubMed ID: 28082254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adverse events associated with long-term use of proton pump inhibitors].
    Reimer C; Bytzer P
    Ugeskr Laeger; 2012 Sep; 174(39):2289-93. PubMed ID: 23006222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of long-term PPI therapy.
    Reimer C
    Best Pract Res Clin Gastroenterol; 2013 Jun; 27(3):443-54. PubMed ID: 23998981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proton Pump Inhibitors: Review of Emerging Concerns.
    Nehra AK; Alexander JA; Loftus CG; Nehra V
    Mayo Clin Proc; 2018 Feb; 93(2):240-246. PubMed ID: 29406201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adverse effects of proton pump inhibitors: should we worry about long-term exposure?].
    Roulet L; Vernaz N; Giostra E; Gasche Y; Desmeules J
    Rev Med Interne; 2012 Aug; 33(8):439-45. PubMed ID: 22284952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing.
    Dharmarajan TS
    J Am Med Dir Assoc; 2021 Jan; 22(1):15-22. PubMed ID: 33321078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study.
    Labenz C; Wörns MA; Adarkwah CC; Galle PR; Schattenberg JM; Kostev K
    Aliment Pharmacol Ther; 2020 Sep; 52(6):1042-1050. PubMed ID: 32729625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association of proton pump inhibitors and hypomagnesemia in the community setting.
    Markovits N; Loebstein R; Halkin H; Bialik M; Landes-Westerman J; Lomnicky J; Kurnik D
    J Clin Pharmacol; 2014 Aug; 54(8):889-95. PubMed ID: 24771616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use.
    Chowdhry M; Shah K; Kemper S; Zekan D; Carter W; McJunkin B
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1717-1721. PubMed ID: 29514412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of the long-term use of proton pump inhibitors.
    Thomson AB; Sauve MD; Kassam N; Kamitakahara H
    World J Gastroenterol; 2010 May; 16(19):2323-30. PubMed ID: 20480516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities.
    Patterson Burdsall D; Flores HC; Krueger J; Garretson S; Gorbien MJ; Iacch A; Dobbs V; Homa T
    J Am Med Dir Assoc; 2013 Jun; 14(6):429-32. PubMed ID: 23583000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia: a case-control study.
    Hess MW; de Baaij JH; Broekman MM; Bisseling TM; Haarhuis BJ; Tan AC; Te Morsche RH; Hoenderop JG; Bindels RJ; Drenth JP
    Pharmacogenet Genomics; 2017 Mar; 27(3):83-88. PubMed ID: 27926584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypomagnesemia and proton-pump inhibitors.
    Famularo G; Gasbarrone L; Minisola G
    Expert Opin Drug Saf; 2013 Sep; 12(5):709-16. PubMed ID: 23808631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe?
    Corsonello A; Lattanzio F
    Trends Cardiovasc Med; 2019 Aug; 29(6):353-360. PubMed ID: 30389278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indications and safety of proton pump inhibitor drug use in patients with cancer.
    Triadafilopoulos G; Roorda AK; Akiyama J
    Expert Opin Drug Saf; 2013 Sep; 12(5):659-72. PubMed ID: 23647006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Severe hypomagnesaemia due to proton pump inhibitor use].
    van den Berg S; Scheer MLJ; Holman ND
    Ned Tijdschr Geneeskd; 2018 Aug; 162():. PubMed ID: 30182626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.
    Lewis JR; Barre D; Zhu K; Ivey KL; Lim EM; Hughes J; Prince RL
    J Bone Miner Res; 2014 Nov; 29(11):2489-97. PubMed ID: 24825180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton pump inhibitors--uncommon adverse effects.
    Oh S
    Aust Fam Physician; 2011 Sep; 40(9):705-8. PubMed ID: 21894279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum magnesium and proton-pump inhibitors use: a cross-sectional study.
    Faulhaber GA; Ascoli BM; Lubini A; Mossmann M; Rossi G; Geib G; Furlanetto TW
    Rev Assoc Med Bras (1992); 2013; 59(3):276-9. PubMed ID: 23680271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.